Electromed (NYSE:ELMD) Downgraded to Buy Rating by StockNews.com

Electromed (NYSE:ELMD) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday.

Electromed Trading Up 2.7 %

ELMD stock traded up $0.82 during trading on Thursday, reaching $31.12. The stock had a trading volume of 107,788 shares, compared to its average volume of 95,098. The firm has a market cap of $263.21 million, a PE ratio of 43.22 and a beta of 0.31. The stock’s 50 day moving average is $28.40 and its two-hundred day moving average is $21.41. Electromed has a 52 week low of $9.90 and a 52 week high of $31.88.

Electromed (NYSE:ELMD) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.03 by $0.13. The firm had revenue of $14.67 million during the quarter. Electromed had a return on equity of 15.32% and a net margin of 11.34%.

Insider Buying and Selling

In other Electromed news, Director Andrew Summers sold 12,731 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $29.98, for a total value of $381,675.38. Following the completion of the sale, the director now owns 165,755 shares of the company’s stock, valued at $4,969,334.90. This trade represents a 7.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 14.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Electromed

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC purchased a new position in shares of Electromed in the 3rd quarter valued at $215,000. Wilmington Savings Fund Society FSB purchased a new position in Electromed in the third quarter valued at about $226,000. Walleye Capital LLC purchased a new position in Electromed in the third quarter valued at about $274,000. Marshall Wace LLP bought a new position in Electromed in the second quarter worth about $256,000. Finally, Navellier & Associates Inc. purchased a new stake in shares of Electromed during the third quarter valued at about $368,000. Institutional investors own 40.82% of the company’s stock.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.